Study on the effect of different administration modes of sufentanil on perioperative stress response of patients undergoing abdominal surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045613

Enrollment

Unknown

Registered

2021-04-19

Start date

2021-04-26

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal diseases

Interventions

Experimental group:Multi-target concentration drug delivery

Control group:Single target concentration dosing

Eligibility

Sex/Gender

All

Age

18 Years to 68 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with ASA I-III (18-68 years old); 2. Patients undergoing elective abdominal surgery; 3. The patient voluntarily participated in this trial and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Combined with severe cardiopulmonary disease, severe liver and kidney damage (Child-Pugh B, C, CKD3-5), nervous system disease or abnormal mental state; 2. Combined with endocrine system and metabolic system diseases; 3. Addicted to tobacco or alcohol or abuse of sedative or analgesic drugs, drinking coffee or tea-related liquids within 48 hours before surgery; 4. Patients who are allergic to narcotic drugs; 5. Patients who have used opioids recently.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Sufentanil plasma drug concentration;Catecholamine;IL-6;	—

Secondary

Measure	Time frame
Quality of postoperative recovery;Cortisol;	—

Countries

China

Contacts

Public ContactCai Hongwei

Xiangya Hospital Central South University

chw2005@163.com+86 13973176608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026